BG-60366

N/A

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameBG-60366
Drug Alias NameChimeric degradation activating compound (CDAC) targeting EGFRBG-60366
ClassificationSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionEpidermal growth factor receptor erbB1 degraders
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesThailandNew Zealand +[11] 
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesBeOne Medicines Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBeigene (Suzhou) Biotechnology Co Ltd
Inactive CompaniesBeOne Medicines Ltd
Active IndicationsN/A
Inactive IndicationsCarcinoma, Non-Small-Cell LungLung Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A